FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
By Lori Solomon HealthDay Reporter
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved indication for Keytruda in endometrial carcinoma.
The approval is for Keytruda, an anti-programmed death receptor-1 (anti-PD-1) therapy, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
The FDA based its approval on data from the phase 3 KEYNOTE-868 trial, in which Keytruda plus carboplatin and paclitaxel followed by Keytruda alone reduced the risk for disease progression or death by 40 percent in patients whose cancer was mismatch repair-proficient (pMMR) and by 70 percent in patients whose cancer was mismatch repair-deficient (dMMR), compared with placebo with carboplatin and paclitaxel followed by placebo alone. For patients whose cancer was pMMR, median progression-free survival with Keytruda was 11.1 months compared with 8.5 months for placebo. For dMMR, median progression-free survival was not reached with Keytruda versus 6.5 months for placebo.
"Endometrial cancer is now the most common gynecologic cancer in the United States, and deaths from the disease are projected to surpass deaths from ovarian cancer in 2024, underscoring the need for treatment advances for more patients," Gursel Aktan, M.D., Ph.D., from Merck Research Laboratories, said in a statement. "This approval represents the first and only anti-PD-1-based option for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status, building on the established role of Keytruda in certain types of advanced endometrial carcinoma as monotherapy and in combination with Lenvima."
Approval of this indication for Keytruda was granted to Merck.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer
THURSDAY, Feb. 20, 2025 -- Short-course vaginal cuff brachytherapy (VCB) is noninferior to standard regimens for short-term quality of life in people with early-stage endometrial...
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
MONDAY, Oct. 21, 2024 -- Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent...
Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer
WEDNESDAY, Aug. 14, 2024 -- For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.